First probiotics-and-cognition meta-analysis (2020)
Researchers pooled five randomized trials covering 297 patients with Alzheimer's disease or mild cognitive impairment. The analysis found probiotics improved cognition (effect size 0.37) and lowered markers of inflammation and oxidative stress.
Showed promise but was judged insufficient evidence for clinical use.
Set the template for larger trials and flagged the need for longer follow-up.
This 2026 trial is the next step in that line — a placebo-controlled test of a specific multistrain product with blood biomarkers as endpoints.
